Please check your internet connection and try again.
## TUSQ-QD
### Overview
TUSQ-QD is a once-daily combination product containing **Theophylline (xanthine bronchodilator), **U**ncaria tomentosa (cat's claw, antioxidant and anti-inflammatory properties), **S**albutamol (short-acting beta-2 agonist), and **Quercetin (flavonoid, antioxidant and anti-inflammatory properties). Its specific use and efficacy for respiratory conditions are not widely established by robust clinical trials in major medical literature.
### Primary Indications
* Generally marketed for symptomatic relief of bronchospasm associated with conditions such as asthma and COPD.
### Adult Dosing
* Dosing varies significantly by formulation and manufacturer. A common approach involves **one tablet once daily**. Specific dose titration may be necessary based on individual response and tolerability.
### Pediatric Dosing
* Information on established pediatric dosing for TUSQ-QD is limited. Use in pediatric populations should be based on clinical judgment and available evidence for individual components, if applicable.
### Dose Adjustments
* **Renal Impairment:** No specific guidance is readily available. Theophylline clearance can be reduced in renal impairment.
* **Hepatic Impairment:** No specific guidance is readily available. Theophylline metabolism is reduced in hepatic impairment.
* **Elderly:** Monitor for increased sensitivity to side effects, particularly with the theophylline component.
### Contraindications
* Hypersensitivity to any of the active ingredients.
* Avoid in patients with known hypersensitivity to xanthine derivatives or beta-2 agonists.
* Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, seizure disorders, or peptic ulcers.
### Adverse Effects
* **Theophylline:** Nausea, vomiting, headache, insomnia, nervousness, tremor, arrhythmias, seizures.
* **Salbutamol:** Tremor, nervousness, palpitations, tachycardia, headache, dizziness.
* **Uncaria tomentosa and Quercetin:** Generally considered well-tolerated, but allergic reactions are possible. Gastrointestinal upset may occur.
### Key Drug Interactions
* **Theophylline:**
* **CYP1A2 inhibitors** (e.g., cimetidine, erythromycin, ciprofloxacin): Increase theophylline levels.
* **CYP1A2 inducers** (e.g., rifampin, phenytoin, phenobarbital): Decrease theophylline levels.
* **Beta-blockers:** May antagonize the effects of salbutamol and increase bronchospasm risk.
* **Diuretics:** May increase theophylline clearance.
* **Salbutamol:** Additive effects with other sympathomimetics.
### Monitoring
* **Theophylline levels:** Therapeutic range is typically 10-20 mcg/mL. Monitor closely, especially with dose changes or suspected interactions.
* **Vital signs:** Heart rate, blood pressure.
* **Clinical response:** Assess for improvement in respiratory symptoms.
* **Signs of adverse effects:** Monitor for any new or worsening symptoms.
### Clinical Pearls
* Due to the limited robust clinical data for the combination product, its use may be considered off-label or experimental in some regions.
* Theophylline has a narrow therapeutic index and requires careful monitoring.
* Individual components (theophylline, salbutamol) are available as monotherapy and may be preferred if specific component titration is needed.
* Patients should be advised to report any adverse effects promptly.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature before making clinical decisions. Dosing and recommendations may vary.
